KZIA - Kazia Therapeutics L...

Kazia Therapeutics Limited

KZIA

NASDAQ

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

5.6 USD

0.21 (3.75%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Operating Data Balance Sheet Free Cash Flow Free Cash Flow Buildup Terminal Value Intrinsic Value Equity Value WACC

FMP

Home Terms of Service Privacy Policy Blog Careers FAQs Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.